Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

US10399932B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• James Aaron Balog · Lambertville, US
• Emily Charlotte Cherney · Newtown, US
• Jay A. Markwalder · New London, US
• Steven P. Seitz · Swarthmore, US
• Weifang Shan · Princeton, US
• David K. Williams · Cinnaminson, US
• Audris Huang · Princeton, US
• Susheel Jethanand Nara · Mumbai, IN
• Saumya Roy · Bengaluru, IN
• Soodamani Thangavel · Krishnagiri, IN
• Ramesh Kumar Sistla · Bengaluru, IN
• Srinivas Cheruku · Bengaluru, IN
• Srinivasan Thangathirupathy · Hosur, IN
• Yadagiri Kanyaboina · Bengaluru, IN
• Nagalakshmi Pulicharla · Bengaluru, IN

Key dates

• Filing date: Apr 1, 2016
• Grant date: Sep 3, 2019
• Expiry date: Apr 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.